-
NICE approves Keytruda combination therapy for NSCLC through CDF
pharmaceutical-technology
August 09, 2019
The UK’s healthcare regulator the National Institute of Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) combined with two chemotherapy drugs ...
-
NICE recommends Lokelma treatment for hyperkalaemia
europeanpharmaceuticalreview
August 05, 2019
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
-
AstraZeneca’s ovarian cancer drug Olaparib gets NICE approval
pharmaceutical-technology
July 30, 2019
AstraZeneca has obtained the National Institute for Health and Care Excellence (NICE) approval for use of its olaparib drug as a first-line maintenance therapy to treat gynaecological cancers patients on the National Health Service (NHS) in England, UK.
-
UK’s NICE backs Novartis breast cancer drug Kisqali
pharmaceutical-technology
July 22, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has approved Novartis’ drug Kisqali (ribociclib) in combination with fulvestrant for the treatment of certain patients with advanced breast cancer.
-
NICE recommends risankizumab to treat severe psoriasis
europeanpharmaceuticalreview
July 15, 2019
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.
-
NICE recommends Pfizer’s dacomitinib for NSCLC patients
pharmaceutical-technology
July 09, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Pfizer’s dacomitinib (Vizimpro) as a first-line treatment for non-small-cell lung cancer (NSCLC) patients on the National Health Service (NHS).
-
NICE endorses dacomitinib for treatment of lung cancer
europeanpharmaceuticalreview
July 09, 2019
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
-
NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro instead
fiercepharma
July 09, 2019
England’s cost watchdogs won’t get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer challenger.
-
Decision by NICE for the use of osimertinib to be appealed
europeanpharmaceuticalreview
July 08, 2019
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
-
NICE nod for Blincyto
pharmatimes
June 19, 2019
The National Institute for Health and Care Excellence (NICE) has announced the recommendation of Amgen’s Blincyto (blinatumomab) for treating acute lymphoblastic leukaemia (ALL). The indication is for patients in first complete remission with minimal resi
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
